Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Can-Fite BioPharma ( (CANF) ).
On January 20, 2026, Can-Fite BioPharma announced it had completed patient enrollment in its multicenter, open-label Phase 2a pancreatic cancer trial of Namodenoson, which is testing safety, clinical activity and pharmacokinetics in patients with advanced pancreatic adenocarcinoma who have failed at least one prior therapy. The company reported that the primary safety endpoint has been met to date with a favorable safety profile at the tested oral dose, positioning Namodenoson—already granted U.S. Orphan Drug Designation for pancreatic cancer—as a potentially important new option in a setting of high unmet need and setting expectations for top-line efficacy data in the third quarter of 2026, a milestone that could influence Can-Fite’s clinical strategy and perception of its oncology franchise.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs targeting multi-billion-dollar markets in cancer, liver and inflammatory diseases. Its lead candidate Piclidenoson is in Phase 3 development for psoriasis, while liver drug Namodenoson is in Phase 3 for hepatocellular carcinoma, Phase 2b for MASH and Phase 2a for pancreatic cancer, with additional proof-of-concept in several other tumor types; a third candidate, CF602, is being developed for erectile dysfunction, and the company reports an extensive safety database across more than 1,600 treated patients.
Average Trading Volume: 509,788
Technical Sentiment Signal: Sell
Current Market Cap: $5.67M
For a thorough assessment of CANF stock, go to TipRanks’ Stock Analysis page.